Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13 Gastrointestinal Stromal Tumors 12 Leukemia, Myeloid, Chronic-Phase 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Leukemia 3 Neoplasms 2 Melanoma 2 Burkitt Lymphoma 2 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Thyroid Cancer, Papillary 1 Squamous Cell Carcinoma of Head and Neck 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1 Philadelphia Chromosome 1 Neoplasm, Residual 1 Myeloproliferative Disorders 1 Lymphangioleiomyomatosis 1 Leukemia, Myeloid 1 Leukemia, Biphenotypic, Acute 1 Hypereosinophilic Syndrome 1 Hematologic Diseases 1 Head and Neck Neoplasms 1 Graft vs Host Disease 1 Digestive System Neoplasms 1 Desmoid Tumors 1 Dermatofibrosarcoma 1 Congenital Bone Marrow Failure Syndromes 1 Chordoma 1 Carcinoma, Adenoid Cystic 1

Interventions

Sirolimus 2 temsirolimus 1 carbon-11 acetate 1 Valproic Acid 1 Respiratory Function Tests 1 Phlebotomy 1 Immunoglobulin G 1 Imatinib Mesylate 1 Genetic Testing 1 Disulfides 1 Cetuximab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphangioleiomyomatosis × Imatinib Mesylate × 1 year × Clear all

NCT06889168 2026-01-21

LAMP-2

Columbia University

Phase 1 Recruiting

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡